Newsroom

Eingefärbtes Rasterelektronenmikroskopbild einer Zelle
News
Scientists at the Würzburg-based Helmholtz Institute for RNA-based Infection Research (HIRI) and the Helmholtz Centre for Infection Research (HZI) in Braunschweig demonstrate for the first time how ZAP, a protein of the human immune defence system, inhibits the replication mechanism of the SARS-CoV-2 coronavirus and can reduce the viral load by 20-fold. The findings were published today in the journal Nature Communications. They may help develop antiviral agents in the fight against the pandemic.
10.12.2021
Myxobakterien
News
Since 2017, interested citizen scientists can collect soil samples as part of the "Sample’ das Saarland" campaign and send them to the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS). The HIPS is a site of the Helmholtz Centre for Infection Research (HZI) in collaboration with Saarland University. Scientists at HIPS search for new types of myxobacteria in the samples, and grow and examine them in the laboratory. These globally distributed, predatory soil bacteria are capable of producing an enormous variety of chemical substances, so-called microbial natural products, which often represent excellent starting points for the development of drugs. At HIPS, the main focus is on molecules that are able to kill other bacteria. The idea behind this is that if myxobacteria can use these substances in the soil to hunt down other bacteria, scientists may be able to develop new drugs from the same substances to fight bacterial infections in humans. The focus is particularly on resistant pathogens for which the antibiotics available up to now can no longer be used with the usual success.
09.12.2021
Grafik Männchen
News
Between July 2020 and August 2021, the Epidemiology Department of the Helmholtz Centre for Infection Research (HZI) in Braunschweig examined the blood of approximately 26,000 individuals for antibodies against the SARS-CoV-2 coronavirus as part of the nationwide “MuSPAD” study. For samples collected between July and October 2020, it became evident that one to three per cent of the people had experienced a SARS-CoV-2 infection after the first wave. By the end of the third wave, the seroprevalence had increased but remained at less than 15 per cent at most study sites. Therefore, while there were two to five actual infections for every reported infection during the first wave, this ratio - and thus the number of undetected cases - decreased in the second and third waves. These results were recently published in the international issue of Deutsches Ärzteblatt. In addition, a preprint publication of another study investigating the immune response after vaccination against SARS-CoV-2 based on samples from the MuSPAD study is under review.
08.12.2021
Portrait Thomas Pietschmann
Interview
A conversation about the direction of research at the HZI with Prof Thomas Pietschmann, who is the head of the "Experimental Virology" department at the HZI and director of the Experimental Virology Institute at the TWINCORE - Centre for Experimental and Clinical Infection Research
06.12.2021
Luca Cicin-Sain
Interview
The cold season has arrived along with the question of whether a vaccination against influenza makes sense in times of the ongoing pandemic. And when is the right time for the third vaccination, i.e. the booster vaccination against Covid-19?
03.12.2021
Portrait Dr. Sahamoddin Khailaie
News
On the occasion of its 15th anniversary, the MTZ®foundation presented the SonderMTZ®-Award 2021 in Erkrath-Trills. The award winner is Dr Sahamoddin Khailaie from the department "Systems Immunology" headed by Prof Michael Meyer-Hermann at the Helmholtz Centre for Infection Research (HZI) in Braunschweig. The prize was awarded in recognition of his outstanding achievements in the field of Medical Systems Biology and Systems Medicine. The award ceremony took place during the 13th PhD Symposium of the HZI on 2 December 2021.
03.12.2021

HZI in the media

Quelle:

 

Pressemitteilung Helmholtz-Zentrum für Infektionsforschung HZI ...

10.12.2025
|
LaborPraxis

Medikament Tolcapon identifiziert. Das HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung (HZI) in Kooperation ...

01.12.2025
|
Homburg

... wissenschaftlicher Ko-Direktor des Helmholtz Zentrums für Infektionsforschung (HZI). Thomas Pietschmann engagiert sich seit 2023 im ...

28.11.2025
|
juraforum.de

Dr. Alexander Titz, group leader at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS). “Finding new ways to disrupt its

28.11.2025
|
ARCHYDE

... “, sagte die Leiterin der Epidemiologie am Braunschweiger Helmholtz-Zentrum für Infektionsforschung.

 

Lange betonte, flächendeckende ...

28.11.2025
|
Evangelische Zeitung

... ein Zentrum für Quantentechnologie entstehen und das Helmholtz-Institut für Pharmazeutische Forschung ausgebaut werden.

 

Mehr ...

27.11.2025
|
Tagesschau

Euro werden investiert in die Erweiterung des Helmholtz-Instituts für Pharmazeutische Forschung Saarland (HIPS). Und ...

27.11.2025
|
ZEIT online

s drug tolcapone. HIPS is a site of the Helmholtz Center for Infection Research (HZI) in collaboration with Saarland University.

 

The

26.11.2025
|
Medical Xpress

... erhielt das Projekt „Citrapeutics“ vom Helmholtz-Zentrum für Infektionsforschung (HZI) in Braunschweig eine Förderung in Höhe ...

25.11.2025
|
Bionity.COM

led by Hannover Medical School (MHH) and the Helmholtz Center for Infection Research (HZI) has now discovered clear molecular signatures for

24.11.2025
|
Medical Xpress

Medizinischen Hochschule Hannover (MHH) und dem Helmholtz-Zentrum für Infektionsforschung (HZI), hat nun eindeutige molekulare Signaturen ...

24.11.2025
|
DeutschesGesundheitsPortal

Braunschweig. Das Helmholtz-Zentrum für Infektionsforschung (HZI) bringt anlässlich seines 60. Jubiläums seine Forschung vom 3. ...

22.11.2025
|
Regional Heute

Register now for the HZI-Newsletter